You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205211 - 205220 of 207699 results
  1. A Culture-Free Platform for Rapid Pathogen Identification

    SBC: HELIXBIND, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): A Culture-Free Platform for Rapid Pathogen Identification Project Summary Sepsis is a one of the leading causes of morbidity and mortality in the US, with more than 751,000 confirmed cases occurring every year and 210,000 mortalities. This high mortality rate (~30%) means that nearly 600 patients a day succumb to sepsis-related infections. In addition to the hu ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. TOPIC 438- PREDICTION OF CANCER DRUG RESISTANCE TO AID IN CLINICAL DECISION MAKING I-CORPS PERIOD OF PERFORMANCE: MAR. 1, 2023 THRU APRIL 30, 2023.

    SBC: PATHODYNAMICS LLC            Topic: 438

    Cancer is the second leading cause of death behind heart disease with ~600,000 deaths annually according to the CDC.Approximately 90% of cancer deaths are attributed to drug resistance making ita major health problem.Both intrinsic and acquired drug resistance in cancers have been attributed to the presence of genetic variant in the genes involved in growth or apoptosis. However, many of the varia ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. PHASE I-TOPIC 431- DRUG DELIVERY BY ENDOESOPHAGEAL LAVAGE (EEL) TO TREAT ESOPHAGEAL CANCER

    SBC: ISOLA THERAPEUTICS INC            Topic: 431

    Cancer is the second leading cause of death in the United States and esophageal cancer has the 6th lowest survival rate for all cancers. Systemic drug therapy is first-line therapy for widely metastatic esophageal cancer, but is limited by systemic toxicity, patient eligibility, or cost. The proprietary Isola system consists of a drug delivery catheter, tubing, heating element, and a drug lavage s ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. FY23. SBIR TOPIC 167 PHASE I: AN ARRAY-BASED MULTIPLEX IMMUNOASSAY FOR POSTMORTEM TOXICOLOGY SCREENING

    SBC: HIGH THROUGHPUT BIOLOGY INC            Topic: 167

    Currently, suspected drug overdoses represent more than 1 in 6 death investigations, and both coroner and medical examiner offices are facing overwhelming caseloads that require comprehensive toxicology analysis. Therefore, there is a critical and immediate need to improve the workflow in suspected fatal overdose cases with new postmortem toxicology screening tools. This Phase I project from High ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. ARPA-H O1 SBIR PHASE II- NOVEL TELEHEALTH INSTRUMENTS FOR ASSESSING PEDIATRIC WELL-BEING. PROJECT TITLE: DIGITAL ASSESSMENT OF CHILDREN'S CONDITIONS USING ARTIFICIAL INTELLIGENCE (""DACCS AI"")

    SBC: BELLETORUS CORPORATION            Topic: AH01

    This project explores applying artificial intelligence (AI), transfer learning, and assessment of mobile phone images of pediatric throat, otoscopy ear, and skin conditions to help enable remote pediatric care of colds, sore throats, ear infections and other diseases.

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. SBIR TOPIC 401 PHASE II:

    SBC: MALCOVA INC            Topic: 401

    As long as breast cancer remains a pervasive health concern, the need for ever-improving breast cancer imaging and radiation therapy technologies will exist. Design changes – to incorporate new hardware technologies or methods - may trigger the need for clinical trials to ensure safety and assess performance. Conducting a clinical trial is not only expensive, but often takes years for patient re ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. ARPA-H-01 PHASE II SBIR: A SMART AI-BASED DIGITAL HEALTH FRAMEWORK FOR ENHANCING PEDIATRIC WELLNESS.

    SBC: Medentum Innovations Inc.            Topic: AH01

    The primary purpose of the project is to build preliminary AI algorithms to detect Ear Nose Throat (ENT) and respiratory (asthma) issues in a pediatric rural population with the intention of facilitating telehealth diagnosis and treatment, and minimizing burdens related to accessing health care in rural areas.

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. ARPA-H SBIR PHASE II TOPIC ARPA-H 04 INTRA-OPERATIVE CONTRAST AGENTS

    SBC: TRACE BIOSCIENCES INC            Topic: AH04

    This project plans to synthesize and characterize novel nerve-specific fluorescence guided surgery (FGS) contrast agents to select a bright, water-soluble lead compound for clinical translation with optimal nerve visualization, functional assessment performance, and clinically relevant pharmacology and toxicology (pharm/tox) profiles for follow-on Investigational New Drug-enabling studies and firs ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC 453: A DIGITAL TOOL TO INTEGRATE CANCER PREVENTION WITHIN PRIMARY CARE.

    SBC: LUCIDACT INC            Topic: 453

    LucidAct Inc. (LucidAct) is a Digital Health company that offers connected telemedicine and Remote Patient Monitoring (RPM) solutions specifically designed for patients that are non-tech savvy, living in rural areas, or having cultural and/or language barriers. We provide an end-to-end remote care management solution that combines connected medical devices, telehealth, and intelligent patient enga ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. SBIR PHASE I TOPIC #446- DEVELOPMENT OF SENOTHERAPEUTIC AGENTS FOR CANCER TREATMENT

    SBC: ATUX ISKAY GROUP LLC            Topic: 446

    New therapeutic approaches are urgently required for the treatment of high-risk neuroblastoma where patient outcomes have shown no improvement over recent decades. Many of the agents currently used clinically to arrest cancer cell proliferation of neuroblastoma do so by inducing cellular senescence, or a quasi-senescent state, in which treated neuroblastoma tumors evade chemotherapy. Relapse and d ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government